Table 4.
Subgroup analysis on prognosis
| No. of studies | Rate | 95%CI | I2% | No. of studies | Rate | 95%CI | I2%a | |
|---|---|---|---|---|---|---|---|---|
| dMMR-MSI-H ≥ 5% | dMMR-MSI-H<5% | |||||||
| OS | 4 | 0.79 | 0.72-0.85 | 54.96 | 3 | 0.34 | 0.05-0.72 | - |
| PFS | 5 | 0.57 | 0.44-0.69 | 88.85 | 4 | 0.17 | 0.01-0.46 | 92.19 |
| PD-1 | PD-L1 | |||||||
| OS | 6 | 0.72 | 0.6-0.82 | 82.7 | 1 | 0.11 | 0.05-0.19 | - |
| PFS | 8 | 0.39 | 0.23-0.56 | 93.87 | 1 | 0.43 | 0.32-0.54 | - |
| Monotherapy | Combination therapy | |||||||
| OS | 3 | 0.62 | 0.41-0.80 | - | 4 | 0.62 | 0.2-0.95 | 98.03 |
| PFS | 4 | 0.37 | 0.21-0.54 | 90.64 | 5 | 0.43 | 0.19-0.68 | 94.78 |
aI2 cannot be calculated because the number of studies is 3 or less than 3. One-year overall survival rate (OS), one-year progression-free survival rate (PFS)